How might the clinical development of CELMoDs impact the treatment paradigm for MM?

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked, How might the clinical development of cereblon E3 ligase modulators (CELMoDs) impact the treatment paradigm for multiple myeloma (MM)? During this interview, Paul Richardson discussed the emerging role of CELMoDs in MM. Richardson reviewed the rationale for the development of these agents, what distinguishes them from traditional immunomodulatory agents (IMiDs), and the unmet needs they were designed to address in relapsed and refractory disease (RRMM). Richardson summarized clinical trial results with iberdomide and mezigdomide, highlighted their applications in high-risk and heavily pretreated patients, and emphasized their potential for use in earlier treatment settings and as maintenance therapy. Richardson also outlined ongoing phase III studies and novel combination strategies designed to optimize patient outcomes. This educational resource is independently supported by Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.